Focused On-demand Library for Collectin-11

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Collectin kidney protein 1

Alternative UPACC:

Q9BWP8; A1IGE4; A1IGE5; A1IGE6; A7VJJ2; A7VJJ3; A7VJJ4; A7VJJ5; B2R9M5; B4E1G0; J3KQY9; Q5CZ85; Q7Z6N1


Collectin-11, also known as Collectin kidney protein 1, is a calcium-dependent lectin involved in innate immunity, apoptosis, and embryogenesis. It recognizes high mannose oligosaccharides and certain fucosylated glycans, playing a crucial role in the body's defense mechanism by binding non-self sugars on microorganisms. Additionally, it participates in apoptosis by interacting with DNA on apoptotic cells and aids in embryonic development by guiding cell migration.

Therapeutic significance:

Collectin-11's involvement in 3MC syndrome 2, a disorder characterized by facial dysmorphism, craniosynostosis, and various anomalies, highlights its potential as a target for therapeutic intervention. Understanding the role of Collectin-11 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.